item management s discussion and analysis of financial condition and results of operations overview statements made in this form k  other than those concerning historical information  should be considered forward looking and subject to various risks and uncertainties 
such forward looking statements are made based on management s belief as well as assumptions made by  and information currently available to  management pursuant to the safe harbor provisions of the private securities litigation reform act of the company s actual results may differ materially from the results anticipated in these forward looking statements as a result of a variety of factors  including those identified in business and elsewhere in this annual report on form k for the fiscal year ended june  since its inception  the company has been engaged primarily in the research and development and  more recently  the commercialization of proprietary products relating to the detection  diagnosis and treatment of cancer and infectious diseases 
on june   the fda licensed cea scan for the detection of recurrent and or metastatic colorectal cancer 
on october   the european commission granted marketing authorization for use of the product in the countries comprising the european union 
on february   the company received european commission approval for leukoscan for the diagnosis of osteomyelitis in long bones and in patients with diabetic foot ulcers 
the product is currently under review by the fda for the same indication approved in europe  with the additional indication for diagnosis of acute  atypical appendicitis 
on september   the company received a notice of compliance from the hpb permitting it to market cea scan in canada for recurrent and metastatic colorectal cancer 
the company is also engaged in developing other biopharmaceutical products  which are in various stages of development and clinical testing 
the company has not achieved profitable operations and does not anticipate achieving profitable operations during fiscal year the company will continue to experience operating losses until such time  if at all  that it is able to generate sufficient revenues from sales of cea scan  leukoscan  and its other proposed in vivo products 
further  the company s working capital will continue to decrease until such time  if at all  that the company is able to generate positive cash flow from operations or until such time  if at all  that the company receives an additional infusion of cash from the sale of the company s securities  from other financings or from corporate alliances to finance the company s operating expenses and capital expenditures 
results of operations fiscal year compared to fiscal year revenues for fiscal year were  as compared to  in fiscal year  representing an increase of  the increase was principally due to product sales and an increase in research and development revenues  partially offset by lower interest income 
product sales and royalty revenue for fiscal year was  as compared to  in fiscal year  representing an increase of  of which  is attributable to product sales 
in addition  the company received a license fee of  from a corporate partner 
research and development revenues for fiscal year were  as compared to  in fiscal year  representing an increase of  which is mainly due to an increase in government grant income 
interest income in fiscal year as compared to fiscal year decreased by  primarily as a result of reduced levels of cash available for investment see liquidity and capital resources 
total operating expenses for fiscal year were  as compared to  in fiscal year  representing an increase of  research and development costs increased by  as compared to fiscal year due to ongoing validation of the company s new manufacturing facility and expenses related to the filing of the application to the fda for approval of leukoscan 
general and administrative costs increased by  as compared to fiscal year this increase was principally due to legal expenses of  incurred in connection with a claim against pharmacia upjohn  inc filed in june   marketing expenses for cea scan of  and operating expenses for immunomedics  bv of  which expenses were not significant in the prior year 
net loss for fiscal year was  or per share  as compared to a net loss of  or per share  in fiscal year the greater net loss resulted principally from higher general and administrative expense partially offset by product sales and increased royalty revenues  as explained above 
the net loss per share for fiscal year was impacted by the higher weighted average number of shares outstanding during such period  as compared to fiscal year  due to the conversion of the company s preferred stock see liquidity and capital resources 
fiscal year compared to fiscal year revenues for fiscal year were  as compared to  in fiscal year  representing a decrease of  the decrease was principally due to a decrease in research and development revenue resulting from the termination  in august   of the development and license agreement with pharmacia 
accordingly  research and development revenues decreased by  to  in fiscal year in fiscal year  these revenues totaled  of which  was received from pharmacia 
partly offsetting the decline in research and development revenue was increased interest income of  in fiscal year  as compared to fiscal year  primarily as a result of higher levels of cash available for investment resulting from completion of two financing transactions see liquidity and capital resources 
total operating expenses for fiscal year were  as compared to  in fiscal year  representing an increase of  the increase was due to higher general and administrative expense  largely due to increases in consulting  recruiting and employee benefits expenses of   and  respectively 
the higher consulting expenses were primarily due to a strategic planning study undertaken in fiscal year the higher employee benefits expenses reflected higher payroll taxes  due in part to the exercise of stock options by employees  and higher expenses for executive life insurance for an executive officer of the company 
research and development costs in fiscal year were essentially unchanged from fiscal year net loss for fiscal year was  or per share  as compared to a net loss of  or per share  in fiscal year the greater net loss resulted principally from lower research and development revenue and increased general and administrative expense  as explained above 
the net loss per share for fiscal year was impacted by the higher weighted average number of shares outstanding during such period as compared to fiscal year  which increase was principally due to the conversion of the company s preferred stock see liquidity and capital resources 
liquidity and capital resources at june   the company had working capital of  representing a decrease of  from june   and had no long term debt other than certain lease obligations see note of notes to consolidated financial statements 
the decrease in working capital resulted principally from the funding of operating expenses and capital expenditures 
on june   the company completed an equity financing pursuant to regulation s under the securities act of regulation s  pursuant to which several foreign investors purchased  shares of series d convertible preferred stock the series d preferred for  the terms of the transaction allowed the investors  at their discretion  to convert the series d preferred into shares of the company s common stock during a twenty four month period beginning in june   at a price equal to of the average market price per share over a day trading period surrounding the date of conversion 
dividends on the series d preferred were payable annually  commencing june   on all shares of series d preferred that have not been converted into common stock as of the dividend payment date 
in august   a dividend payment of  was made 
as of june    shares of series d preferred had been converted into  shares of the company s common stock 
in august   the remaining  shares of series d preferred were converted into  shares of the company s common stock 
in addition  during fiscal year  the remaining  shares of the company s series c preferred stock the series c preferred were converted into  shares of the company s common stock 
the company had issued an aggregate of  shares of the series c preferred in fiscal for on august   the company announced that its development and license agreement with pharmacia was terminated and that the company had regained the north american marketing and selling rights for cea scan from pharmacia see legal proceedings 
in february   the company entered into a master lease agreement  which was subsequently amended  pursuant to which the company may lease equipment for research  development and manufacturing purposes having an aggregate acquisition cost of up to  the basic lease payments under the master lease agreement are determined based on current market rates of interest at the inception of each equipment schedule take down and are payable in monthly installments over a four year period 
the lease agreement contains an early purchase option  at an amount that is deemed to be fair value  exercisable no later than ninety days before the thirty sixth installment is due 
on november   december   and april  the company exercised early purchase options on equipment leased on february   april   and june   respectively 
under the lease agreement  continued compliance with certain financial ratios is required and  in the event of default  the company will be required to provide an irrevocable letter of credit which is generally equal to the outstanding balance of lease payments due at the time of default 
as of june   the company has leased equipment with a cost basis aggregating  under the master lease agreement and recorded lease expense for fiscal year of  the company s liquid asset position  as measured by its cash  cash equivalents and marketable securities  was  at june   representing a decrease of  from june  it is anticipated that working capital and cash  cash equivalents  and marketable securities will decrease during fiscal year as a result of planned operating expenses and capital expenditures  offset in part by projected revenues from product sales in the us and europe 
however  there can be no assurance as to the amount of revenues  if any  these products will provide 
at present  the company believes that its financial resources will be sufficient to fund operating expenses and capital expenditures through fiscal year based on reduced spending levels  if necessary 
the company intends to supplement its financial resources from time to time  as market conditions permit  through additional financing  bank loans and collaborative marketing and distribution agreements 
in addition  the company continues to evaluate various programs to raise additional capital and to seek additional revenues from the licensing of its proprietary technology 
at the present time  the company is unable to determine whether any of these activities will be successful and  in such cases  the terms and timing of any definitive agreements or financing 
there can be no assurance that the company will be able to obtain additional funds in the future 
recently issued accounting standards in february  the financial accounting standards board issued statement of financial accounting standards no 
sfas  earnings per share 
sfas establishes standards for computing and presenting earnings per share 
in accordance with the effective date of sfas  the company will adopt sfas as of december  this statement is not expected to have a material impact on the company s financial statements 

